2024/ABM/05/KPO/KPOD.07.07-IW.07-0249/24
NanoSanguis Sp. z o.o. is carrying out the project titled “Dextran Conjugates for Targeted Anticancer Therapy,” co-financed by the Medical Research Agency under the National Recovery and Resilience Plan (KPO), Component D: Efficiency, Availability, and Quality of the Healthcare System, Investment D3.1.1 – Comprehensive Development of Research in the Field of Medical and Health Sciences.

The aim of the project is to develop innovative combinations of cytostatic drugs with a dextran-based carrier and a targeting agent, potentially offering increased efficacy and an improved safety profile for patients.

As part of the project, the following activities are planned: development of synthesis pathways for the conjugates, investigation of drug release kinetics, in vitro studies, comparative cytotoxicity testing, and preliminary studies in mice.
The target group of the project is oncology patients.
The introduction of targeted cancer therapy to the market has the potential to revolutionize oncology treatment and improve patients’ quality of life.

The intended outcome of the project is to improve overall therapeutic efficacy. This can be achieved in two ways:
by increasing patient safety through the use of a lower or equivalent drug dose (depending on the primary therapeutic need), and/or
by increasing the drug dose while maintaining the same level of patient safety.

 

Project value: 2 523 452,23 zł

EU co-financing amount: 2 018 761,77 zł